U.S. Women's Health Market Size, Share & Trends Analysis Report 2024-2030: Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, PCOS

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Sept. 20, 2024 (GLOBE NEWSWIRE) -- The "U.S. Women's healthmarket Size, Share & Trends Analysis Report By Application (Contraceptives, Endometriosis & Uterine Fibroids), By Age (50 Years & Above, Others), By Drug (Prolia, XGEVA), And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.
The U.S. women's health market size is expected to reach USD 29.68 billion by 2030, expanding at a CAGR of 4.04% from 2024 to 2030

The rising prevalence of target diseases is a key driver for the growth of the market. With aging and the increasing prevalence of obesity, the prevalence of osteoarthritis is anticipated to grow. Some of the major factors responsible for hormonal imbalance in women include changes in dietary habits, stress, and consumption of alcohol, which can cause fertility issues. Ovulation problems, polycystic ovarian syndrome (PCOS), and endometriosis are major factors responsible for infertility.

The rise in public funding for family planning services is further driving the market growth. In the U.S., approximately 45% of pregnancies are estimated to be unwanted every year. Despite advancements in contraceptive technology and increased R&D spending on contraceptives, the rate of unplanned pregnancies in the U.S. has remained unchanged for decades.

This has increased the economic burden on low-income families that do not have easy access to modern and more effective methods of contraception. Hence, federal & state governments are actively working toward improving family planning services and access to modern contraceptives.
Moreover, child marriages are most common in underdeveloped and developing economies, often leading to early and unplanned pregnancies. There is a lack of awareness about contraceptives, which amplifies the severity of the problem. According to UNICEF, child marriages decreased by 15% in the past decade. However, the number has not decreased over the years in the U.S. because laws in certain U.S. states allow marriages before 18 years. However, efforts to address child marriage and its impact on women's health are being undertaken in the country, which involve advocating for policy changes, promoting girls' education, raising awareness about the negative consequences of child marriage, and providing support services for affected girls and women.
Furthermore, key players involved in developing and formulating various therapeutics are focusing on collaborations and partnerships to develop novel drugs and maintain their competitive position in the market. For instance, in October 2022, Solera Health announced the launch of first-of-its-kind digital point solutions for women's Health networks to address women's health issues needs. Moreover, in November 2022, Sebela Pharmaceuticals announced the launch of a new division fully dedicated to women's health.
U.S. Women's Health Market Report Highlights

• Based on drug, the Prolia drug segment held the largest revenue share in 2023 and is anticipated to grow at the fastest CAGR over the forecast period owing to the wide adoption of the drug with very less side effects
• Based on application, the contraceptives segment is expected to showcase the fastest CAGR over the forecast period, owing to an increase in awareness about family planning
• Based on age, the others age segment dominated the U.S. women's health industry in 2023, due to the rising concerns of fertility, such as endometriosis, hormonal infertility, and PCOS in this age group
• Based on distribution channel, the hospital pharmacy segment dominated the market in 2023 due to the high stock and availability of women's health therapeutics in the hospital pharmacies
• Key market players are constantly focusing on product launches and geographical expansion to maintain their presence

Companies Featured

• AbbVie, Inc.
• Bayer AG
• Merck & Co., Inc.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.
• Agile Therapeutics
• Amgen, Inc.
• Apothecus Pharmaceutical Corp.
• Eli Lilly and Company
• Ferring B.V.

Key Attributes:

Report Attribute	Details
No. of Pages	130
Forecast Period	2023 - 2030
Estimated Market Value (USD) in 2023	$22.5 Billion
Forecasted Market Value (USD) by 2030	$29.68 Billion
Compound Annual Growth Rate	4.0%
Regions Covered	United States

Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Application outlook
2.2.2. Age outlook
2.2.3. Drug outlook.
2.3. Competitive Insights
Chapter 3. U.S. Women's Health Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising incidence of target diseases
3.2.1.2. Increasing initiatives by government and various organizations
3.2.1.3. Rising publicly funded family planning services
3.2.2. Market restraint analysis
3.2.2.1. Patent expiry of major drugs
3.2.2.2. Lawsuits related to products.
3.2.2.3. Adverse effects associated with use of contraceptive drugs and devices.
3.3. U.S. Women's Health Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.2. PESTEL Analysis
Chapter 4. U.S. Women's Health Market: Application Estimates & Trend Analysis
4.1. Application Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Women's Health Market by Application Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Hormonal infertility
4.4.2. Contraceptives
4.4.3. Postmenopausal osteoporosis
4.4.4. Endometriosis & uterine fibroids
4.4.5. Menopause
4.4.6. Polycystic ovary syndrome (PCOS)
Chapter 5. U.S. Women's Health Market: Drug Estimates & Trend Analysis
5.1. Drug Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Women's Health Market by Drug Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. ACTONEL
5.4.2. YAZ, Yasmin, Yasminelle
5.4.3. FORTEO
5.4.4. Minastrin 24 Fe
5.4.5. Mirena
5.4.6. NuvaRing
5.4.7. ORTHO TRI-CY LO
5.4.8. Premarin
5.4.9. Prolia
5.4.10. Reclast/Aclasta
5.4.11. XGEVA
5.4.12. Zometa
5.4.13. Others
Chapter 6. U.S. Women's Health Market: Age Estimates & Trend Analysis
6.1. Age Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Women's Health Market by Age Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. 50 years and above
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.2. Postmenopausal osteoporosis
6.4.1.3. Endometriosis & uterine fibroids
6.4.1.4. Menopause
6.4.1.5. Others
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2023
For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• U.S. Women's Health Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN20092024004107003653ID1108695642